
Exagen Inc (XGN) Stock Forecast & Price Target
Exagen Inc (XGN) Analyst Ratings
Bulls say
Exagen Inc. has demonstrated a strong revenue growth trajectory, with a reported year-over-year increase of 14.2%, driven primarily by its AVISE CTD product line, which has seen consistent volume growth and a rising average selling price (ASP) currently at $428. The company has also achieved a gross margin expansion of 30 basis points year-over-year, reaching 60.4%, indicating improved operational efficiency. Furthermore, Exagen's strategic focus on optimizing its product offerings and enhancing commercial reimbursement strategies suggests a robust potential for continued revenue growth, with projections indicating a 20.5% revenue increase for FY25 and 14.8% for FY26.
Bears say
Exagen Inc. is facing a challenging financial outlook as its gross margin decreased by approximately 70 basis points to 58.9%, primarily due to strategic investments ahead of a new biomarker launch and projected volume increases. Despite a top-line revenue of $17.2 million in Q2 2025, the company reported a GAAP EPS loss of $0.21, missing consensus expectations, alongside a downward revision of its 2025 revenue estimate to $66.0 million, driven by subdued expectations for the utilization of its AVISE CTD test. Furthermore, Exagen has not achieved profitability and does not anticipate being profitable in 2025, highlighting a reliance on external capital which might not be available under favorable terms, compounded by potential pressures on reimbursement rates for diagnostic tests.
This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.
Exagen Inc (XGN) Analyst Forecast & Price Prediction
Start investing in Exagen Inc (XGN)
Order type
Buy in
Order amount
Est. shares
0 shares